Healthcare / BiotechnologyNasdaqCM
$2.53
-0.03 (-1.17%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-11.2M · quality 52.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
7/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$7M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-243.2%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2012–2025 · 13 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.90x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-13.6M · FCF $-12.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||
| Revenue | — | — | — | — | — | $0.00 | — | — | — | — | $5000.00 | $74599.00 | $101119.00 | $253463.00 | $190145.00 |
| Net Income | $-13.6M | $-13.6M | $-11.9M | $-11.1M | $-27.4M | $-11.4M | $-14.4M | $-3.4M | $-3.8M | $-1.9M | $-1.9M | $-3.4M | $-4.5M | $-3.1M | $-2.4M |
| EBITDA | $-14.0M | $-14.0M | $-12.1M | $-11.5M | $-19.5M | — | — | — | — | — | — | — | — | — | — |
| EPS | -10.36 | -10.36 | -96.78 | -212.00 | -851.25 | -375.00 | — | — | — | -210.00 | -245.00 | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — | — | — | 100.0% | -16.7% | 40.0% | 49.1% | 31.0% |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | -38430.4% | — | — | — | — |
| Net Margin | — | — | — | — | — | — | — | — | — | — | -38341.3% | -4496.3% | -4476.2% | -1210.7% | -1283.5% |
| Balance Sheet | |||||||||||||||
| Debt/Equity | — | — | 0.04 | 0.03 | 0.03 | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 0.98 | 0.98 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||
| Free Cash Flow | $-12.2M | $-12.2M | $-11.2M | $-8.1M | $-9.6M | — | — | — | — | $-1.7M | $-2.2M | $-873305.00 | $-2.7M | $-2.6M | $-2.2M |
| Returns | |||||||||||||||
| ROE | -243.2% | -243.2% | -698.6% | -222.9% | -367.1% | -44.8% | -62.8% | -41.9% | -38.8% | -497.5% | 84.6% | 3913.7% | -374.7% | -183.7% | -95.2% |
| Valuation | |||||||||||||||
| P/B | 0.59 | 0.59 | 1.77 | 1.67 | 2.44 | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||
| Revenue Growth | — | — | — | — | — | — | — | — | — | — | -93.3% | -26.2% | -60.1% | 33.3% | — |
| EPS Growth | 89.3% | 89.3% | 54.3% | 75.1% | — | — | — | — | — | 14.3% | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-65.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-96.78 → -10.36
Residual
-65.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.